Hepatocellular carcinoma - PubMed (original) (raw)
Review
Hepatocellular carcinoma
S A Hussain et al. Ann Oncol. 2001 Feb.
Free article
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer of men and eleventh most common cancer of women world-wide. However, because almost every individual who develops liver cancer dies of the disease, HCC is the third most common cause of the cancer deaths in men and seventh most common in women. The treatment of choice for hepatocellular carcinoma remains surgical resection or liver transplantation, in carefully selected cases. In patients with hepatocellular carcinoma not amenable to surgical intervention a variety of different therapeutic interventions have been investigated. These include direct ablation of the tumour using agents such as ethanol or acetic acid, transcatheter arterial chemoembolization, or systemic chemotherapy. The evaluation of their efficacy is compromised by the paucity of adequately powered randomised clinical trials. The main challenge facing the research community over the next decade is to prioritise the most promising treatments and take these forward into multicentre controlled trials. Even if these fail to improve results, they will help reduce the variation in clinical practice by eliminating anecdotal treatment.
Similar articles
- Treatment of hepatocellular carcinoma.
Masuzaki R, Omata M. Masuzaki R, et al. Indian J Gastroenterol. 2008 May-Jun;27(3):113-22. Indian J Gastroenterol. 2008. PMID: 18787282 Review. - Treatment options in hepatocellular carcinoma today.
Livraghi T, Mäkisalo H, Line PD. Livraghi T, et al. Scand J Surg. 2011;100(1):22-9. doi: 10.1177/145749691110000105. Scand J Surg. 2011. PMID: 21482502 Review. - Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM, Elsayed Z. Abdel-Rahman OM, et al. Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2. Cochrane Database Syst Rev. 2016. PMID: 26905230 Updated. Review. - Radiofrequency ablation for hepatocellular carcinoma.
Nishikawa H, Kimura T, Kita R, Osaki Y. Nishikawa H, et al. Int J Hyperthermia. 2013 Sep;29(6):558-68. doi: 10.3109/02656736.2013.821528. Epub 2013 Aug 12. Int J Hyperthermia. 2013. PMID: 23937321 Review. - Management options for primary hepatocellular carcinoma. An overview.
Paraskevopoulos JA. Paraskevopoulos JA. Acta Oncol. 1994;33(8):895-900. doi: 10.3109/02841869409098452. Acta Oncol. 1994. PMID: 7818921 Review.
Cited by
- Albumin-indocyanine green evaluation of future liver remnant predicts liver failure after anatomical hepatectomy for hepatocellular carcinoma: A dual-center retrospective study.
Nagaoka T, Ogawa K, Sakamoto K, Nakamura T, Imai Y, Nishi Y, Honjo M, Tamura K, Funamizu N, Takada Y. Nagaoka T, et al. Ann Gastroenterol Surg. 2023 Sep 22;8(2):293-300. doi: 10.1002/ags3.12743. eCollection 2024 Mar. Ann Gastroenterol Surg. 2023. PMID: 38455479 Free PMC article. - Nitric oxide/paclitaxel micelles enhance anti-liver cancer effects and paclitaxel sensitivity by inducing ferroptosis, endoplasmic reticulum stress and pyroptosis.
Li H, Deng X, Zhang Z, Yang Z, Huang H, Ye X, Zhong L, Xu G, Liu R, Fang Y. Li H, et al. RSC Adv. 2023 Oct 30;13(45):31772-31784. doi: 10.1039/d3ra04861f. eCollection 2023 Oct 26. RSC Adv. 2023. PMID: 37908648 Free PMC article. - Discovery and Characteristics of a Novel Antitumor Cyclopeptide Derived from Shark.
Li F, Lei M, Xie J, Guo S, Li W, Ren X, Wang T, Lin S, Xie Q, Chen X. Li F, et al. Bioengineering (Basel). 2023 Jun 1;10(6):674. doi: 10.3390/bioengineering10060674. Bioengineering (Basel). 2023. PMID: 37370606 Free PMC article. - Hsa-miR-22-3p inhibits liver cancer cell EMT and cell migration/ invasion by indirectly regulating SPRY2.
Cui S, Chen Y, Guo Y, Wang X, Chen D. Cui S, et al. PLoS One. 2023 Feb 7;18(2):e0281536. doi: 10.1371/journal.pone.0281536. eCollection 2023. PLoS One. 2023. PMID: 36749775 Free PMC article. - Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics.
Fang C, Wang H, Lin Z, Liu X, Dong L, Jiang T, Tan Y, Ning Z, Ye Y, Tan G, Xu G. Fang C, et al. Cancers (Basel). 2022 Jan 4;14(1):231. doi: 10.3390/cancers14010231. Cancers (Basel). 2022. PMID: 35008393 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical